Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.
Number of employees : 121 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Perceptive Advisors LLC ||10,803,857||
|RA Capital Management LP ||9,976,469||
|Ultragenyx Pharmaceutical Inc. ||7,825,797||
|Bain Capital Life Sciences LP ||7,060,353||
|Ecor1 Capital LLC ||5,275,000||
|Gilad D. Hayeem ||4,441,972||
|Matthew Bennett Arnold ||3,933,429||
|Invus Public Equities Advisors LLC ||1,710,000||
|Tavistock Life Sciences Co. (Investment Management) ||1,531,872||
|Ilan Ganot ||1,473,168||
|Company contact information|
Solid Biosciences, Inc.
141 Portland Street
Cambridge, MA 02139
Phone : +1.617.337.4680
Web : http://www.solidbio.com
Sector Bio Therapeutic Drugs
Connections : Solid Biosciences Inc.